PD-1 Inhibitor Clinical Trials

13 recruiting

PD-1 Inhibitor Trials at a Glance

14 actively recruiting trials for pd-1 inhibitor are listed on ClinicalTrialsFinder across 6 cities. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Tianjin, Chengdu, and Guangzhou. Lead sponsors running pd-1 inhibitor studies include Tianjin Medical University Second Hospital, Sun Yat-sen University, and Sichuan University.

Browse pd-1 inhibitor trials by phase

Treatments under study

About PD-1 Inhibitor Clinical Trials

Looking for clinical trials for PD-1 Inhibitor? There are currently 13 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new PD-1 Inhibitor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about PD-1 Inhibitor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 1Phase 2

LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study

Pancreatic CancerPD-1 InhibitorPD-L1+2 more
Zhejiang Provincial People's Hospital10 enrolled1 locationNCT07312422
Recruiting
Phase 2

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

TislelizumabPD-1 InhibitorKidney-sparing+2 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07233252
Recruiting
Phase 2

Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC

Neoadjuvant TherapyPD-1 InhibitorUpper Tract Urothelial Carcinoma+1 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07126119
Recruiting
Phase 2

Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer

Neoadjuvant TherapyTislelizumabPD-1 Inhibitor+3 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07125547
Recruiting
Phase 1

Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment

Gastrointestinal TumorsPersonalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant Therapy
Ruijin Hospital40 enrolled1 locationNCT07067385
Recruiting
Phase 2

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

ChemotherapyPD-1 InhibitorInduction Therapy+2 more
The First Affiliated Hospital of Xiamen University208 enrolled3 locationsNCT06811844
Recruiting
Phase 1Phase 2

Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis

Solid TumorsLeptomeningeal MetastasisCTLA4+2 more
Guangzhou Medical University34 enrolled2 locationsNCT06809530
Recruiting
Phase 2

Neoadjuvant Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer

Colorectal Cancer (CRC)PD-1 InhibitorNeoadjuvant Immunotherapy+2 more
Sun Yat-sen University105 enrolled1 locationNCT06903858
Recruiting

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Hepatocellular CarcinomaPD-1 InhibitorLenvatinib+1 more
Sun Yat-sen University300 enrolled1 locationNCT06333561
Recruiting
Phase 1

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

NSCLCLeptomeningeal MetastasisLow Dose Radiotherapy+1 more
Sichuan University10 enrolled1 locationNCT06431685
Recruiting
Phase 1

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

NSCLCLow Dose RadiotherapyPD-1 Inhibitor+1 more
Sichuan University9 enrolled1 locationNCT05615142
Recruiting
Phase 2

Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell

ChemotherapyEsophageal Squamous Cell CarcinomaPD-1 Inhibitor+1 more
Tang-Du Hospital114 enrolled3 locationsNCT06006650
Recruiting

Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody

Esophageal Squamous Cell CarcinomaPD-1 Inhibitor
Nanfang Hospital, Southern Medical University200 enrolled1 locationNCT05392413
Recruiting
Phase 2

Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma

RadiotherapyCapecitabinePD-1 Inhibitor+1 more
Fifth Affiliated Hospital, Sun Yat-Sen University28 enrolled1 locationNCT05290194